Recently, the breakthrough of the Atezolizumab (anti–PD-L1) plus Bevacizumab (anti-VEGF) and tremelimumab (anti-CTLA4) plus durvalumab (anti-PD1) combination treatments in HCC demonstrated the promise of immunotherapy in the treatment of HCC (3, 4). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.